The estimated Net Worth of Sherry Aulin is at least $721 Thousand dollars as of 2 September 2022. Ms Aulin owns over 18,648 units of Xenon Pharmaceuticals Inc stock worth over $720,745 and over the last 3 years she sold XENE stock worth over $0.
Ms has made over 1 trades of the Xenon Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she exercised 18,648 units of XENE stock worth $129,977 on 2 September 2022.
The largest trade she's ever made was exercising 18,648 units of Xenon Pharmaceuticals Inc stock on 2 September 2022 worth over $129,977. On average, Ms trades about 3,730 units every 0 days since 2021. As of 2 September 2022 she still owns at least 18,648 units of Xenon Pharmaceuticals Inc stock.
You can see the complete history of Ms Aulin stock trades at the bottom of the page.
Sherry Aulin is the Chief Financial Officer at Xenon Pharmaceuticals Inc.
Ms Aulin is 37, she's been the Chief Financial Officer of Xenon Pharmaceuticals Inc since . There are 22 older and no younger executives at Xenon Pharmaceuticals Inc. The oldest executive at Xenon Pharmaceuticals Inc is Michael Tarnow, 74, who is the Independent Chairman of the Board.
Sherry's mailing address filed with the SEC is 200 - 3650 GILMORE WAY, , BURNABY, A1, V5G 4W8.
Over the last 10 years, insiders at Xenon Pharmaceuticals Inc have traded over $12,977,011 worth of Xenon Pharmaceuticals Inc stock and bought 724,015 units worth $2,649,316 . The most active insiders traders include Patrick Machado, Partners L P/Ilbiotechnolog..., and Justin D. Gover. On average, Xenon Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $818,878. The most recent stock trade was executed by Elizabeth A. Garofalo on 8 March 2024, trading 3,500 units of XENE stock currently worth $64,960.
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
Xenon Pharmaceuticals Inc executives and other stock owners filed with the SEC include: